Singapore's Cancer Drug List (CDL) in 2024: Understanding the Latest Changes, Case Studies, and Solutions

About the Webinar

In all its myriad forms, cancer is one of the leading causes of death in Singapore, and it is also one of the fastest-growing healthcare expenditure items for Singapore's healthcare system.

In order to reign in unsustainable cost increases, the Ministry of Health introduced the Cancer Drug List (CDL) policy in 2023, which restricts how cancer treatments can be covered by both public (MediShield) and private (Integrated Shield Plans) insurance plans.

One year on, it is timely to relook how CDL works - including changes made since its inception.

We also examine its impact on you and me, while examining real-world claims and case studies now that the scheme has been in force for some time.

Terms & Conditions: By providing the info below, I confirm that I am the user and/or subscriber of the telephone number(s) provided by me and I consent to receive from Financial Alliance and/or its financial adviser representatives, any marketing, advertising and promotional information, other than that relating to future events organised by Financial Alliance via voice calls, SMS/MMS (text messages) or faxes to my telephone number(s) provided above. I understand I may withdraw any consent I have given at any time by writing in to Financial Alliance Pte Ltd.